Drug-induced Adverse Events
Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
Front Oncol. 2022 Nov 24;12:1046584. doi: 10.3389/fonc.2022.1046584. eCollection 2022.
NO ABSTRACT
PMID:36505772 | PMC:PMC9731103 | DOI:10.3389/fonc.2022.1046584
Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
Front Cardiovasc Med. 2022 Nov 23;9:1041044. doi: 10.3389/fcvm.2022.1041044. eCollection 2022.
NO ABSTRACT
PMID:36505359 | PMC:PMC9727304 | DOI:10.3389/fcvm.2022.1041044
Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis
World J Gastroenterol. 2022 Nov 28;28(44):6294-6309. doi: 10.3748/wjg.v28.i44.6294.
NO ABSTRACT
PMID:36504556 | PMC:PMC9730436 | DOI:10.3748/wjg.v28.i44.6294
Systemic drug-related intertriginous and flexural exanthema-like eruption after Oxford-AstraZeneca COVID-19 vaccine
Clin Mol Allergy. 2022 Dec 12;20(1):13. doi: 10.1186/s12948-022-00179-8.
NO ABSTRACT
PMID:36503530 | DOI:10.1186/s12948-022-00179-8
Comprehensive Multimorbidity Patterns in Older Patients Are Associated with Quality Indicators of Medication-MoPIM Cohort Study
Int J Environ Res Public Health. 2022 Nov 29;19(23):15902. doi: 10.3390/ijerph192315902.
NO ABSTRACT
PMID:36497976 | PMC:PMC9739326 | DOI:10.3390/ijerph192315902
Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies
Cells. 2022 Nov 23;11(23):3736. doi: 10.3390/cells11233736.
NO ABSTRACT
PMID:36496996 | PMC:PMC9736114 | DOI:10.3390/cells11233736
Comparison of the Efficacy and Safety of Adamgammadex with Sugammadex for Reversal of Rocuronium-Induced Neuromuscular Block: Results of a Phase II Clinical Trial
J Clin Med. 2022 Nov 25;11(23):6951. doi: 10.3390/jcm11236951.
NO ABSTRACT
PMID:36498526 | DOI:10.3390/jcm11236951
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Lancet. 2022 Dec 6:S0140-6736(22)02420-5. doi: 10.1016/S0140-6736(22)02420-5. Online ahead of print.
NO ABSTRACT
PMID:36495879 | DOI:10.1016/S0140-6736(22)02420-5
Effect of a Veterans Health Administration Mandate to Case Review Patients with Opioid Prescriptions on Mortality among Patients with Opioid Use Disorder: A Secondary Analysis of the STORM Randomized Control Trial
Addiction. 2022 Dec 10. doi: 10.1111/add.16110. Online ahead of print.
NO ABSTRACT
PMID:36495477 | DOI:10.1111/add.16110
All the benefits of CHX without the side effects
Br Dent J. 2022 Dec;233(11):975. doi: 10.1038/s41415-022-5344-x.
NO ABSTRACT
PMID:36494553 | DOI:10.1038/s41415-022-5344-x
Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids
Toxicol Mech Methods. 2022 Dec 8:1-15. doi: 10.1080/15376516.2022.2156005. Online ahead of print.
NO ABSTRACT
PMID:36482696 | DOI:10.1080/15376516.2022.2156005
Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial
Medicine (Baltimore). 2022 Dec 2;101(48):e31982. doi: 10.1097/MD.0000000000031982.
NO ABSTRACT
PMID:36482530 | DOI:10.1097/MD.0000000000031982
Post COVID-19 vaccination side effects and associated factors among vaccinated health care providers in Oromia region, Ethiopia in 2021
PLoS One. 2022 Dec 8;17(12):e0278334. doi: 10.1371/journal.pone.0278334. eCollection 2022.
NO ABSTRACT
PMID:36480564 | DOI:10.1371/journal.pone.0278334
Qualitative analysis of telephonic comprehensive medication review content and delivery
J Am Pharm Assoc (2003). 2022 Nov 17:S1544-3191(22)00386-7. doi: 10.1016/j.japh.2022.11.006. Online ahead of print.
NO ABSTRACT
PMID:36481091 | DOI:10.1016/j.japh.2022.11.006
A Rare Case of Phentermine-Induced Nonischemic Cardiomyopathy
Cureus. 2022 Nov 5;14(11):e31114. doi: 10.7759/cureus.31114. eCollection 2022 Nov.
NO ABSTRACT
PMID:36479398 | PMC:PMC9720414 | DOI:10.7759/cureus.31114
Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
Cancer Sci. 2022 Dec 7. doi: 10.1111/cas.15684. Online ahead of print.
NO ABSTRACT
PMID:36478334 | DOI:10.1111/cas.15684
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity
Diabetes Obes Metab. 2022 Dec 7. doi: 10.1111/dom.14932. Online ahead of print.
NO ABSTRACT
PMID:36478142 | DOI:10.1111/dom.14932
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome
JCI Insight. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030.
NO ABSTRACT
PMID:36477362 | DOI:10.1172/jci.insight.163030
Pneumonitis associated with bortezomib in a patient with multiple myeloma
J Oncol Pharm Pract. 2022 Dec 7:10781552221143789. doi: 10.1177/10781552221143789. Online ahead of print.
NO ABSTRACT
PMID:36476141 | DOI:10.1177/10781552221143789